Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?

Authors

Jasmina Ivanova (ORCID: https://orcid.org/0000-0002-4028-9676)
Birol Emir (ORCID: https://orcid.org/0000-0003-1787-4938)
Hongbo Yang (ORCID: https://orcid.org/0000-0003-2741-8418)
Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
Daniel J. George (ORCID: https://orcid.org/0000-0002-0836-8542)
Adina Zhang (ORCID: https://orcid.org/0000-0001-7451-7756)
Alexandra Greatsinger (ORCID: https://orcid.org/0000-0001-8576-8614)
Krishnan Ramaswamy (ORCID: https://orcid.org/0000-0003-0890-0268)
Betty Thompson
Qing Liu (ORCID: https://orcid.org/0000-0003-1357-4866)
Agnes Hong

Institutions

Cedars-Sinai Medical Center (US)
Pfizer (United States) (US)
Durham VA Medical Center (US)
Astellas Pharma (United States) (US)
Analysis Group (United States) (US)

Publication Details

Journal: Future Oncology
Published: 2025-04-25
DOI: https://doi.org/10.1080/14796694.2025.2485752
Citations: 1
Primary Topic: Prostate Cancer Treatment and Research
Type: article
Field-Weighted Citation Impact: 1.52

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?

Jasmina Ivanova, Birol Emir, Hongbo Yang, Stephen J. Freedland et al.

Apr 25, 2025

1 citations

Future Oncology

Prostate Cancer Treatment and Research

1.52

article

Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?

Jasmina Ivanova, Birol Emir, Hongbo Yang, Stephen J. Freedland, Daniel J. George, Adina Zhang, Alexandra Greatsinger, Krishnan Ramaswamy, Betty Thompson, Qing Liu, Agnes Hong

April 25, 2025article en

1 citations

Abstract

No abstract available for this paper.

Future OncologyVol. 21(11)

Cedars-Sinai Medical Center (US), Pfizer (United States) (US), Durham VA Medical Center (US), Astellas Pharma (United States) (US), Analysis Group (United States) (US)

Openalex Percentile: Top 19%

Prostate Cancer Treatment and Research

1.52

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.